Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001771919 | SCV002001595 | uncertain significance | not provided | 2021-01-06 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Invitae | RCV000660863 | SCV002290325 | uncertain significance | Telangiectasia, hereditary hemorrhagic, type 2 | 2020-11-21 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACVRL1 protein function. This variant has been observed in individual(s) with pulmonary arterial hypertension (Invitae). ClinVar contains an entry for this variant (Variation ID: 548119). This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 193 of the ACVRL1 protein (p.Leu193Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. |
Institute of Human Genetics, |
RCV000660863 | SCV000778829 | likely pathogenic | Telangiectasia, hereditary hemorrhagic, type 2 | 2018-06-28 | no assertion criteria provided | clinical testing |